Cancer in intensive care unit patients with COVID-19

Moiseev, Sergey; Avdeev, S. N.; Brovko, Michail; Akulkina, Larisa; Fоmin, Victоr

doi:10.1016/j.jinf.2020.05.053

Cited by 10 publications

(6 citation statements)

References 5 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Whilst these studies indicate that the prevalence of cancer in patients with COVID‐19 may be higher than in the general population, not all studies have found this to be the case. For example, in 1 307 patients who were admitted to intensive‐care units (ICUs) in Russia, only 2·4% had a history of cancer (none of which were haematological) and the authors concluded this was a similar prevalence to that in the general population 10 . Zhou et al 11 .…”

Section: Resultsmentioning

confidence: 99%

“…For example, in 1 307 patients who were admitted to intensive-care units (ICUs) in Russia, only 2Á4% had a history of cancer (none of which were haematological) and the authors concluded this was a similar prevalence to that in the general population. 10 Zhou et al 11 showed that in 191 patients who were admitted into one of two hospitals in the Wuhan province only two had a history of carcinoma. Other cohorts (n = 41-201) of patients with COVID-19 have also been published with only one patient with malignancy in each of the cohorts.…”

Section: Is Cancer a Risk Factor For Developing Covid-19?mentioning

confidence: 99%

See 1 more Smart Citation

Haematological cancers and the risk of severe COVID‐19: Exploration and critical evaluation of the evidence to date

El‐Sharkawi

Iyengar

2020

Br J Haematol

View full text Add to dashboard Cite

Summary From the outset of the COVID‐19 pandemic, patients and healthcare professionals have been concerned that a history of haematological malignancy will lead to an increased risk of severe COVID‐19. This led to the UK government advising patients with blood cancers to shield, massive re‐organisation of NHS haematology and cancer services, and changes in treatment plans for thousands of patients. Given the unknown effects that relaxation of social‐distancing measures will have on the infection rate, we review the evidence to date to see whether a history of haematological malignancy is associated with increased risk of COVID‐19. Multivariable analysis of large population studies, taking other known risk factors into account, do indicate that patients with haematological malignancy, especially those diagnosed recently, are at increased risk of death from COVID‐19 compared to the general population. The evidence that this risk is higher than for those with solid malignancies is conflicting. There is suggestive evidence from smaller cohort studies that those with myeloid malignancy may be at increased risk within the blood cancer population, but this needs to be confirmed on larger studies. Ongoing large collaborative efforts are required to gain further evidence regarding specific risk factors for severe complications of COVID‐19.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Is Cancer a Risk Factor For Developing Covid-19?mentioning

confidence: 99%

Haematological cancers and the risk of severe COVID‐19: Exploration and critical evaluation of the evidence to date

El‐Sharkawi

Iyengar

2020

Br J Haematol

View full text Add to dashboard Cite

show abstract

“…[12] Likewise, another study conducted in Wuhan, China disclosed that among cancer patients, lung cancer was 25% [13]. Further related studies in Russia stated that as was expected, lung and breast cancers were the most common type malignancies within cancer patients (2.4%) [14]. In addition, another finding from a similar study indicates that in England, patients with a uterine cancer had an incidence and prevalence rate of 8.6% & 6.3% and for bone cancer were 28.3% and 5.7% respectively [15].…”

Section: Resultsmentioning

confidence: 82%

A Comparative Study of the Impact of Coronavirus (COVID -19) on the Therapeutic Practices of Cancer Patients in the Kingdom of Saudi Arabia and Egypt

Mahmoud¹,

Alshammari²,

Alshammari³

et al. 2021

JPRI

View full text Add to dashboard Cite

Cancer patients are considered one of the most vulnerable to infection with Corona virus (COVID-19), especially who are elderly, multiple comorbidities, and are often immunosuppressed by their cancer or therapy. The immune system of cancer patients is very weak compared to the healthy individuals, so, morbidity and mortality of any serious infections expected to be high among them. This research aims to study the impact of COVID-19 pandemic on cancer patients practices in Saudi Arabia (KSA) and compare with the result in Egypt. It was conducted through a well-structured questionnaire, among cancer patients either online (KSA) or paper questionnaire (Egypt). The questionnaire consists of 16 questions about Scio-demographic and changes in time and method of treatment (chemotherapy and radiotherapy), postponed of surgical operations. Our results showed significant differences between KSA and Egypt hospital practices; cancer department was affected by postponed appointment (54.8% & 63.3%), diagnosis (32.7% & 60%) and treatment of cancer patients (37.1% & 63.3%) respectively. Also, postponed of chemotherapy/radiotherapy (56.8% & 73.3%), surgical operations (45% & 43.3%), an increase in the deterioration of cancer by (35.5% & 23.3%), switching from parenteral injection to oral (27.8% & 56.7%) and changing in the drug doses (19.5% & 40%) in KSA and Egypt respectively. We can conclude that management of cancer patients during COVID-19 pandemic of great importance and so, switching from parenteral to oral, prolongation of the treatment period and postponed of some surgical operations gave a good opportunity to maintain adequate care of cancer patient with minimum exposure of patients to infection.

show abstract

“…Data analyses was performed by Microsoft Excel and Stata version 15 software (StataCorp, Texas, USA)(Stata including population characteristics (including total number of study subjects, age, sex and outcome i.e. mortality associated with SARS CoV-2 infection).The included studies were from China (n = 9) (Dai et al, 2020;He et al, 2020;Meng et al, 2020;Zhang H et al, 2020;Tian et al,2020), the United States (n = 5) (Kalinsky et al, 2020;Luo et al, 2020;Mehta et al, 2020;Robilotti et al, 2020;, Italy (n = 4) (Bogani et al, 2020;Fattizzo et al, 2020;Gallo et al, 2020;Stroppa et al, 2020), Spain (n = 2) (Rogado et al, 2020;Yarza et al, 2020), the United Kingdom (n =5) (Aries et al, 2020;Russell et al 2020;Shah et al, 2020;Shi et al, 2020;Lee et al, 2020), France (n = 2) (Basse et al, 2020;Vuagnat et al, 2020), Brazil (n=1) ( de Melo et al, 2020), Belgium (n = 1) ( Lattenist et al, 2020) , Russia (n=1) ( Moiseev et al, 2020) and one study from Europe included patients from 8 countries (Garassino et al, 2020). Recruitment in these 18 studies was from December 17 th 2019 to June17 th 2020.…”

Section: Discussionmentioning

confidence: 99%

Impact of Underlying Comorbidities on Mortality in SARS-COV-2 Infected Cancer Patients: A Systematic Review and Meta-Analysis

Kaur

Thakur

Paika

et al. 2021

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Background: The evidence has shown that SARS CoV-2 infected patients with comorbidities are more likely to have severe disease sequel and mortality. In SARS-CoV-2 infected cancer patients risks associated with other underlying comorbidities might vary from those in non-cancer SARS CoV-2 infected patients. The relative impact of different underlying health conditions among patients with cancer and SARS CoV-2 infection remains yet to be explored. This systematic review aims to explore the prevalence of comorbidities among cancer patients with SARS CoV-2 infection and their impact on mortality. Methods: Online databases PubMed, Embase, Scopus and Web of science were searched for articles published between 9th July 2019 to July 8th 2020.Studies of cancer patients (>18 years) with diagnosis of SARS CoV-2 infection, published in English were included. A random-effects modelling for the meta-analyses was applied to assess the pooled prevalence and odds ratio for mortality due to comorbidities in SARS CoV-2 infected cancer patients. Results: Total 31studies with 4086 SARS-CoV-2 infectedcancer patientsmet the inclusion criteria. Most prevalent co-morbidities in cancer patients with SARS CoV-2 infection were hypertension [42.3% (95%CI:37.5- 47.0)], diabetes [17.8% (95% CI: 15.3-20.4)] and cardiovascular diseases [16.7% (95%CI:12.9-20.4)].The risk of mortality (pOR) was significantly higher in individuals with hypertension[1.6(95%CI 1.24-2.00)], cardiovascular diseases [2.2 (95%CI 1.49- 3.27)], chronic obstructive pulmonary diseases [1.4(95% CI 1.05-2.00)] and diabetes [1.35(95%CI 1.06-1.73)]. Conclusion: Our results indicates that the mortality in SARS-CoV-2 infected cancer patients is affected by preexisting non-cancer comorbidities. By identifying the comorbidities predictive for mortality, clinicians can better stratify the risk of cancer patients presenting with SARS-COV-2, on their initial contact with health services.

show abstract

Cancer in intensive care unit patients with COVID-19

Cited by 10 publications

References 5 publications

Haematological cancers and the risk of severe COVID‐19: Exploration and critical evaluation of the evidence to date

Haematological cancers and the risk of severe COVID‐19: Exploration and critical evaluation of the evidence to date

A Comparative Study of the Impact of Coronavirus (COVID -19) on the Therapeutic Practices of Cancer Patients in the Kingdom of Saudi Arabia and Egypt

Impact of Underlying Comorbidities on Mortality in SARS-COV-2 Infected Cancer Patients: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About